The Hindu Business Line : Arch Pharma to co-market Sibra ARVs

Arch Pharmalabs Ltd of Mumbai has announced that it has signed a co-marketing agreement with the Hyderabad-based Sibra Pharmaceuticals Ltd in the area of anti-retro virals (ARVs).

Under the agreement, Arch would market the entire range of Sibra's ARVs on an exclusive basis both for the Indian and global markets, the company said in a press release here. Starting off with the local markets, Arch said it is confident of supplying active pharmaceutical ingredients (APIs) around the world by supporting Sibra on regulatory affairs.

Further, Arch said Sibra would also have access to its other support services, including process development, supply chain management and market access. According to the Arch Chairman and Managing Director, Mr Ajit Kamath, the company would seek more such co-marketing arrangements and expand its offerings across therapeutic segments.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
DS Constructions completes expressway

Indiabulls to allot pref shares to Oberon

Sunil Mittal is CEO of the Year

DCM Shriram may hive off Hariyali

PM to lay stone for MRPL complex

Arch Pharma to co-market Sibra ARVs

CII moots viability funding for social infrastructure

DLF IPO to hit the market by July 15

Shapoorji Pallonji group bets big on overseas deals

Havell's sets Rs 2,000-cr sales target